For many older men, nighttime bathroom trips can disrupt sleep and reduce overall well-being. Enlarged prostates, common with age, can cause urinary symptoms that worsen over time.
What Happened
A new analysis of clinical trials found that adding vibegron to standard prostate treatment may reduce nighttime trips to the bathroom.
The study included 1,362 men from two randomized trials. After 12 weeks, men using vibegron with prostate medication had 0.8 fewer toilet trips per day, one fewer episode of urgency, and 0.3 fewer nighttime trips.
These changes were statistically significant but small. Overactive bladder symptom scores dropped an average of 2.36 points—below the 3-point threshold for clinical meaning.
How Vibegron Works
Vibegron, sold as Gemtesa, is an oral drug approved by the U.S. FDA in 2020 for overactive bladder.
It does not shrink the prostate. Instead, it relaxes the bladder muscle, allowing it to hold more urine before triggering the urge to urinate.
It is taken daily and has been tested in men already receiving treatment for benign prostate enlargement.
Key Findings from Long-Term Trials
Participants had to urinate at least eight times a day and feel urgency at least three times. The trial was double-blind and placebo-controlled, making it one of the most rigorous studies.
After 24 weeks, 276 men continued treatment for another 28 weeks. Among those who took vibegron for a full year, results showed:
- 2.4 fewer trips to the toilet per day
- Nearly 3 fewer episodes of urinary urgency per day
- One fewer nighttime trip to urinate
These results suggest long-term benefits. However, the extension phase lacked a placebo group, so it’s unclear how much of the improvement came from vibegron.
Why This Matters
Frequent nighttime trips can interfere with sleep and daily routines. Even small symptom improvements may enhance quality of life for men with enlarged prostates.
Many patients are unaware that combination therapy is an option.
Limitations and Open Questions
Research on vibegron in prostate cases is still developing. Studies differ in:
- Baseline symptom severity
- Dosage used
- Follow-up duration (8 to 24 weeks)
- Type of prostate treatment given
This variation makes direct comparisons difficult.
The absence of a placebo group in the long-term phase limits how much we can attribute the improvements to vibegron itself.
What to Watch Next
Longer studies are needed to confirm whether benefits grow over time. Researchers must assess results across diverse patient groups and treatment plans.
Until then, vibegron remains a treatment option many patients and doctors may not know about.
For more on this research, see the original source at sciencealert.com.
Sources & further reading
Featured image: One Drug May Reduce Nighttime Bathroom Trips in Men With Enlarged Prostates. Via original publisher. Image source
